---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210286"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:50:07.381489+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amylyx Q1 net loss $41.3M; Phase 3 avexitide topline data in Q3 2026

## Summary
- Net loss of $41.3M ($0.37 per share) vs $35.9M ($0.42) in Q1 2025; cash used in operations.
- Cash $279.8M at March 31, 2026, down from $317.0M; runway expected into 2028.
- R&D expense rose to $27.6M, driven by avexitide trial costs and $4M Gubra milestone.
- Phase 3 LUCIDITY for avexitide (PBH) enrollment complete; topline data in Q3 2026.
- Early biomarker data from LUMINA Phase 1 for AMX0114 (ALS) expected at ENCALS June 2026.

## SEC filing metadata
- accession: 0001193125-26-210286
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312526210286/0001193125-26-210286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312526210286/amlx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210286
- JSON: https://secwatch.observer/filing/0001193125-26-210286.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210286.txt

## Source-grounded claims
- claim_id: f79ed0d06ead6cc7700bdd90f9c52a559602d919
  claim: Amylyx Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share, EPS $0.37 per share.
  evidence_excerpt: Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share, compared to net loss of $35.9 million, or $0.42 per share, for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000119312526210286/0001193125-26-210286-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.